GlassScriptPhysician profile
Samuel A Agahiu
NPI 1992967020
$6,416.36
in general payments reported to CMS, 2019-2025
21 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $416 · 2021: $108 · 2022: $1,017 · 2023: $825 · 2024: $1,842 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Consulting Fee: $1,000 · Travel and Lodging: $7.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.00 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $7.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,156.10 | 2022-2024 | Jesduvroq, Benlysta |
| Amgen INC. | $703.83 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $570.60 | 2019-2023 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $541.97 | 2020-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $528.05 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $466.83 | 2021-2023 | |
| Horizon Therapeutics Plc | $405.83 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $403.82 | 2019-2025 | Farxiga |
| Ardelyx, INC. | $360.07 | 2025 | Xphozah 30 Mg, Ibsrela |
| Aurinia Pharma U.S., INC. | $295.07 | 2024-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $201.40 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $161.54 | 2024-2025 | |
| Novo Nordisk INC | $137.63 | 2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.95 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $124.70 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $111.69 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Ani Pharmaceuticals, INC. | $43.15 | 2023-2025 | Purified Cortrophin Gel |
| Recor Medical INC | $20.74 | 2025 | Paradise Ultrasound Renal Denervation System |
| Janssen Pharmaceuticals, INC | $18.40 | 2019 | |
| Ascendis Pharma Endocrinology INC | $16.59 | 2025 | Yorvipath |
| Opko Pharmaceuticals, LLC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Agahiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.